Medicine and Dentistry
Adjuvant Therapy
20%
Adverse Event
10%
Arm
8%
Combination Therapy
25%
Disease Exacerbation
8%
Diseases
8%
Event Free Survival
30%
Immune Checkpoint Inhibitor
50%
Immune-Related Adverse Events
25%
Immunotherapy
20%
Ipilimumab
100%
Maintenance Therapy
8%
Melanoma
58%
Metastatic Melanoma
50%
Neoplasm
26%
Nivolumab
100%
Overall Survival
8%
Prognostic Factor
8%
Quality of Life
8%
Recurrence Free Survival
10%
Survival Time
10%
Systemic Therapy
10%
Treatment Duration
33%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
25%
Antibiotics
50%
Beta Glucuronidase
10%
Combination Therapy
25%
Disease Exacerbation
8%
Diseases
8%
Glucuronide
10%
Immune Checkpoint Inhibitor
50%
Immunosuppressive Agent
10%
Intestine Flora
10%
Ipilimumab
50%
Melanoma
8%
Metastatic Melanoma
50%
Mycophenolate Mofetil
50%
Mycophenolic Acid
50%
Neoplasm
16%
Nivolumab
50%
Overall Survival
8%
Pharmacokinetics
10%
Therapeutic Drug Monitoring
20%
